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data shown in Figures 6 and 7 are derived from the same blot. We have addressed the final request raised 
by Reviewer #4 in the attached Response to Reviewers’ Comments and provided original blots. 
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MANUSCRIPT NO. BC-D-16-00018R1 
RESPONSE TO REVIEWERS’ COMMENTS  
 
RESPONSE TO REVIEWER #1 
No comment 
 
RESPONSE TO REVIEWER #2 
Comment #1: The authors have corrected the mistakes and performed additional experiments to 
answer the questions, so my suggestion is that the manuscript can be considered for publication 
now. 
Response #1: Thank you. 
 
RESPONSE TO REVIEWER #3 
Comment #1: The authors have made significant improvement in scientific and technical content 
of the manuscript. The manuscript is now in acceptable format. 
Response #1: Thank you. 
 
RESPONSE TO REVIEWER #4 
Comment #1: The authors have addressed most of my main concerns and the additional 
experiments have improved the manuscript. I would like to see, however, whether the Western 
blot data from Figs 6 and 7 are derived from the same blot and would thus like to ask for the 
original blot data of the three replicates. Quantification of expression levels is only possible when 
samples are run on the same gel and have been processed and exposed in a similar manner. As 
such, depicting quantitative Western blots as in Figs 6 and 7 is irritating and not recommended. 
Response #1: I can confirm that the Western blot data from the new n=3 experiments performed 
for the Figures 6 and 7 in the revised manuscript are derived from the same blot. We agree with 
the reviewer that quantification of expression levels is only possible when samples are run on the 
same gel and have been processed and exposed in a similar manner (our standard practice). In 
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Original blots used for the three experimental 
replicates used for Figure 6 
 
Representative blots are from Experiment 1 
 
Data Used: Lanes 1 (vehicle), 4 (Pam3CSK4) 
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Original blots used for the three experimental replicates used for 
Figure 7C 
 
Representative blots are from… 
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Corticosteroids are effective anti-inflammatory therapies widely utilized in chronic 
respiratory diseases. But these medicines can lose their efficacy during respiratory infection 
resulting in disease exacerbation. Further in vitro research is required to understand how 
infection worsens lung function control in order to advance therapeutic options to treat 
infectious exacerbation in the future. In this study, we utilize a cellular model of bacterial 
exacerbation where we pretreat A549 lung epithelial cells with the synthetic bacterial 
lipoprotein Pam3CSK4 (a TLR2 ligand) to mimic bacterial infection and tumor necrosis 
factor α (TNFα) to simulate inflammation. Under these conditions, Pam3CSK4 induces 
corticosteroid insensitivity; demonstrated by substantially reduced ability of the 
corticosteroid dexamethasone to repress TNF-induced interleukin 6 secretion. We then 
explored the molecular mechanism responsible and found that corticosteroid insensitivity 
induced by bacterial mimics was not due to altered translocation of the glucocorticoid 
receptor into the nucleus, nor an impact on the NF-κB pathway. Moreover, Pam3CSK4 did 
not affect corticosteroid-induced upregulation of anti-inflammatory MAPK deactivating 
phosphatase - MKP-1. However, Pam3CSK4 can induce oxidative stress and we show that a 
proportion of the MKP-1 produced in response to corticosteroid in the context of TLR2 
ligation was rendered inactive by oxidation. Thus to combat inflammation in the context of 
bacterial exacerbation we sought to discover effective strategies that bypassed this road-
block. We show for the first time that known (FTY720) and novel (theophylline) activators of 
the phosphatase PP2A can serve as non-steroidal anti-inflammatory alternatives and/or 
corticosteroid-sparing approaches in respiratory inflammation where corticosteroid 
insensitivity exists.  
 
Keywords: corticosteroid insensitivity, TLR2, MKP-1, PP2A 
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1. Introduction 
Corticosteroids are front-line anti-inflammatory therapies that are widely used to treat people 
with chronic lung disease. In asthma, although corticosteroids have proven clinical efficacy, 
it is increasingly recognized that their anti-inflammatory effectiveness can vary widely 
depending on disease context (such as when people with asthma are experiencing respiratory 
infections). This is known as corticosteroid insensitivity. In severe asthma, the degree of 
insensitivity increases to become corticosteroid resistance; a steroid-refractory condition 
experienced by 10% of people with asthma. Thus, the impact of corticosteroid insensitivity is 
increasingly recognized as a major problem limiting the efficacy of anti-inflammatory 
therapy in chronic respiratory disease (reviewed in (Ammit, 2013; Chung, 2013)). Moreover, 
corticosteroids are much less effective in chronic obstructive pulmonary disease (COPD) than 
in asthma, and this is considered due to relative corticosteroid insensitivity that exists in 
COPD (Marwick and Chung, 2010). To combat inflammation, steroid dose can be increased, 
but this is not ideal. Thus, alternative anti-inflammatory strategies that could effectively treat 
inflammation when corticosteroid insensitivity exists are urgently required. 
Cellular models of corticosteroid insensitivity are invaluable in vitro tools in our quest to 
develop novel and efficacious pharmacotherapeutic strategies to treat respiratory disease in 
the future. They are an essential first step towards elucidating the mechanisms responsible for 
respiratory infections and the exacerbation of chronic lung diseases. This was highlighted in a 
recent review by Saturni et al. (Saturni et al., 2015), and demonstrated by Papi et al. (Papi et 
al., 2013), where A549 lung epithelial cells exposed in vitro to rhinoviral infection resulted in 
corticosteroid insensitivity. The molecular mechanisms responsible were explored and shown 
to be due to reduced nuclear translocation of the receptor for corticosteroids – the 
glucocorticoid-receptor (GR) (Papi et al., 2013). Ligand-activated GR translocation is a 
critical step in corticosteroid function; without this, GRs are unable to interact in a cis- or 
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trans-manner to exert transcriptional control. Notably, upregulation of a critical, 
corticosteroid-induced, anti-inflammatory protein – mitogen-activated protein kinase 
phosphatase 1 (MKP-1) - was attenuated by rhinoviral infection and contributed to 
corticosteroid insensitivity. While the impact of respiratory viruses on corticosteroid 
insensitivity have begun to be uncovered (reviewed in (Saturni et al., 2015)), the influence of 
bacterial infection warrants further investigation. 
Accordingly, we have established an in vitro cellular model of bacterial exacerbation utilizing 
the synthetic bacterial lipoprotein Pam3CSK4 (Alkhouri et al., 2014; Hirota et al., 2013; 
Manetsch et al., 2012c). The impact of this TLR2 ligand on corticosteroid insensitivity and 
the role played by GR translocation and MKP-1 upregulation was previously unknown. We 
address this herein and show that Pam3CSK4 induces corticosteroid insensitivity in A549 
lung epithelial cells. Interestingly, the mechanism is not via retardation of GR translocation 
into the nucleus, the mechanism responsible for rhinoviral-induced corticosteroid 
insensitivity (Papi et al., 2013). Instead we reveal that while the total amount of anti-
inflammatory MKP-1 produced in response to corticosteroid in the context of TLR2 ligation 
was unaffected, a proportion of MKP-1 was rendered inactive by oxidation of the catalytic 
cysteine. MKP-1 is one of the major ways in which corticosteroids achieve anti-inflammatory 
action (Che et al., 2014; Issa et al., 2007; King et al., 2009; Manetsch et al., 2012a; Quante et 
al., 2008; Rahman et al., 2014). Given that this anti-inflammatory pathway is less effective 
under in vitro conditions mimicking bacterial exacerbation, we were compelled to uncover 
alternative, non-steroidal anti-inflammatory strategies. We focused on activators of 
ubiquitous serine/threonine phosphatase protein phosphatase 2A (PP2A). PP2A 
dephosphorylates a number of proteins that control inflammatory cell signalling (Junttila et 
al., 2008; Miskolci et al., 2003; Shanley et al., 2001) and our recent research has revealed that 
known and novel PP2A activators can also have substantial anti-inflammatory effect in the 
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context of respiratory inflammation (Patel et al., 2015; Rahman et al., 2016; Rahman et al., 
2015). In this study we are the first to examine the impact of PP2A activators in an in vitro 
model of bacterial exacerbation, and notably, we show that PP2A activators can repress 
inflammation when corticosteroid insensitivity exists. 
 6 
2. Material and Methods 
2.1 Chemicals 
Pam3CSK4 was purchased from InVivoGen (San Diego, CA), tumor necrosis factor  
(TNFα) was from R&D Systems (Minneapolis, MN) and FTY720 was from Cayman 
Chemical Company (Ann Arbor, MI). Unless otherwise specified, all chemicals used in this 
study were purchased from Sigma-Aldrich (St. Louis, MO).  
 
2.2 Cell culture 
The human alveolar epithelial cell line (A549) was cultured in Ham's F-12K (Kaighn's) 
medium (Invitrogen, Carlsbad, CA) supplemented with penicillin (100 U/ml), streptomycin 
(100 μg/ml), and fetal calf serum (10%). All experiments were performed after an overnight 
serum-starvation period (14-16 h) in Ham's F-12K supplemented with sterile BSA (0.1%), 
and cells were stimulated with 4 ng/ml TNFα in accordance with previous publications 
(Cornell et al., 2009; Rahman et al., 2015). A minimum of three experimental replicates 
performed on separate days were used for each experiment. 
 
2.3 ELISA 
IL-6 ELISA was performed according to the manufacturer’s instructions (BD Biosciences 
Pharmingen, San Diego, CA).    
 
2.4 Western blotting 
To examine GR and p65 NF-κB translocation, cytoplasmic and nuclear protein extraction 
was performed using NE-PER nuclear and cytosolic extraction kit according to the 
manufacturer's instructions (Thermo Fisher Scientific, Rockford, IL). Western blotting was 
performed using rabbit polyclonal IgG antibodies raised against GR (E-20: Santa Cruz 
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Biotechnology, Santa Cruz, CA) or an XP® rabbit monoclonal antibody against p65 NF-κB 
(D14E12: Cell Signaling Technologies, Danvers, MA). Mouse monoclonal antibodies to α-
tubulin (IgG1, DM1A: Santa Cruz Biotechnology) and rabbit polyclonal antibodies to lamin 
A/C (Cell Signaling Technology) were used as loading controls for the cytosolic and nuclear 
fractions, respectively. To measure MKP-1upregulation in whole cell lysates, MKP-1 was 
quantified by Western blotting using a rabbit polyclonal antibody against MKP-1 (C-19: 
Santa Cruz Biotechnology). IκB-α degradation and heme oxygenase 1 (HO-1) upregulation 
were also detected using rabbit polyclonal antibodies from Santa Cruz (C19) or Cell 
Signaling Technologies (P249), respectively. For all experiments in whole cell lysates, α-














) and total JNK were from Cell Signaling Technology. Primary 
antibodies were detected with goat anti-rabbit and anti-mouse HRP-conjugated secondary 
antibodies (Cell Signaling Technology) and visualized by enhanced chemiluminescence 
(PerkinElmer, Wellesley, MA).  
 
2.5 MKP-1 oxidation 
The method used to measure oxidized MKP-1 was an adaptation of the PROP (purification of 
reversibly oxidized proteins) technique developed by Templeton et al. (Templeton et al., 
2010; Victor et al., 2012). A549 cells were subjected to oxidative stress conditions (see 
experimental text) before commencing the PROP procedure. Briefly, the non-oxidized thiols 
were blocked using N-ethylmaleimide, then the oxidized thiols were reduced with 
dithiothrietol and eluted with thiol affinity chromatography (thiopropyl sepharose 6B: GE 
Healthcare, Little Chlafont, UK). Oxidized MKP-1 was then measured using Western blot 
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and the degree of oxidation compared to native MKP-1 measured in whole cell lysates run in 
parallel. 
 
2.6 Statistical analysis 
Statistical analysis was performed using either the Student's unpaired t test, one-way 
ANOVA with Fisher’s post-hoc multiple comparison test or two-way ANOVA followed by 
Bonferroni’s post-test. P values <0.05 were sufficient to reject the null hypothesis for all 
analyses. Data are mean+SEM of n≥3 independent replicates. 
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3. Results 
3.1 TLR2 ligand Pam3CSK4 induces corticosteroid insensitivity in A549 cells 
Herein we adapt a clinically-relevant model of corticosteroid insensitivity (Papi et al., 2013) 
to mimic bacterial exacerbation in vitro and demonstrate that exposure to a synthetic bacterial 
lipoprotein (TLR2/TLR1 ligand; Pam3CSK4) induces relative corticosteroid insensitivity. 
We chose to use 1 µg/ml Pam3CSK4 based on our earlier studies with this bacterial mimic 
(Hirota et al., 2013; Manetsch et al., 2012c). When A549 cells were pretreated with 
Pam3CSK4, the dose-dependent repression of TNF-induced IL-6 secretion achieved with 
dexamethasone was significantly altered (Figure 1: P<0.05). This is particularly notable at 
0.01-1 µM dexamethasone, where the inhibitory impact of dexamethasone on cytokine 
secretion from A549 cells is significantly attenuated by Pam3CSK4 (Figure 1: P<0.05). 
 
3.2 Corticosteroid insensitivity induced by Pam3CSK4 is not due to altered 
translocation of GR into the nucleus 
We then wished to explore the molecular mechanism responsible for corticosteroid 
insensitivity exerted by the TLR2 ligand. Corticosteroids mediate their actions via interaction 
with the cytosolic GR that then undergoes translocation into the nucleus. As this is an 
essential step necessary for corticosteroid action, we examined whether the molecular basis 
of corticosteroid insensitivity established by Pam3CSK4 is due to a retardation of GR 
translocation. We address this in Figure 2, where the effect of Pam3CSK4 pretreatment on 
GR translocation induced by dexamethasone (0.0001-1 µM) was assessed under two 
experimental conditions: i.e. in the absence (Figure 2A) or presence of stimulation with 
TNFα (Figure 2B). Cytoplasmic and nuclear protein extracts were prepared and nuclear entry 
of GR determined by Western blotting, compared with α-tubulin and lamin A/C as loading 
controls for the cytosolic and nuclear fractions, respectively. As shown in Figure 2A, GR 
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resides in the cytosol and is undetectable in the nucleus under unstimulated conditions. After 
treatment with dexamethasone however, GR undergoes translocation in a concentration-
dependent manner. Notably, dexamethasone-induced GR translocation is unaffected by 
Pam3CSK4 (Figure 2A). These results were independent of stimulation with TNF; as 
confirmatory experiments (performed in Figure 2B) show a similar pattern of GR 
translocation in cells that have been treated with TNF. Taken together these experiments 
demonstrate that corticosteroid insensitivity induced by Pam3CSK4 is not due to altered 
translocation of GR into the nucleus. 
 
3.3 Corticosteroids have no effect on TNFα-induced IκB-α degradation and p65 NF-κB 
nuclear entry 
Corticosteroids also have the potential to form inhibitory interactions with the pro-
inflammatory DNA-binding transcription factors, such as NF-κB (reviewed in (Ammit, 
2013)). To exclude the possible inhibition of NF-κB activity as a mechanism for 
corticosteroid insensitivity we took two experimental approaches. Firstly, we showed that 
corticosteroids had no effect on TNFα-induced IκB-α degradation (Figure 3). IκB-α is a 
constitutively expressed protein that forms an inhibitory complex with NF-κB. TNFα can 
induce the degradation of IκB-α, freeing NF-κB from its inhibitory control and allowing it to 
exert transcriptional impact. This is shown in Figure 3, where the basal level of inhibitory 
IκB-α is significantly degraded by TNFα. Notably, corticosteroids do not affect TNFα-
induced IκB-α degradation in A549 cells. We examined this after pretreating cells with a 
range of dexamethasone concentrations (0.0001-1 µM) and, as shown in Figure 3, there was 
no significant effect on the extent of IκB-α degradation achieved with TNFα in the presence 
of dexamethasone (P<0.05). Secondly, we examined whether dexamethasone repressed the 
translocation of the p65 NF-κB subunit into the nucleus. Cells were pretreated with a range of 
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dexamethasone concentrations (0.0001-1 µM) and the effect on TNFα-induced nuclear 
translocation assessed. As shown in Figure 4, corticosteroids have no effect on the nuclear 
entry of p65 NF-κB induced by TNFα. Taken together, the results presented in Figures 3 and 
4 confirm that corticosteroids do not act to repress the TNFα-induced NF-κB pathway.  
 
3.4 Pam3CSK4 does not affect corticosteroid-induced upregulation of anti-
inflammatory MKP-1 
Thus far we have shown that Pam3CSK4 reduces the anti-inflammatory efficacy of 
corticosteroids on TNF-induced cytokine production without affecting GR nor p65 NF-κB 
translocation. We (Che et al., 2014; Manetsch et al., 2012b; Quante et al., 2008; Rahman et 
al., 2014) and others (Issa et al., 2007; King et al., 2009) have shown that a major mechanism 
responsible for the anti-inflammatory action of corticosteroids is via the upregulation of 
MAPK-deactivating phosphatase – MKP-1; thus, we investigated whether impaired MKP-1 
upregulation was responsible for corticosteroid insensitivity induced by bacterial ligand 
Pam3CSK4. This is explored in Figure 5, where MKP-1 upregulation in whole cell lysates of 
A549 cells was compared by Western blotting (Figure 5A) and analyzed by densitometry 
(Figure 5B). We demonstrate that TNF induces significant upregulation of MKP-1 protein 
(3.2±0.5-fold compared to vehicle-treated cells (designated as 1) (P<0.05)); in alignment with 
previous studies in A549 cells (King et al., 2009). MKP-1 is corticosteroid-inducible (King et 
al., 2009) and accordingly, TNF-induced MKP-1 in A549 cells pretreated with 
dexamethasone is significantly enhanced at 0.01-1 µM (Figure 5B: P<0.05). However, when 
we examine the influence of Pam3CSK4 pretreatment on MKP-1 upregulation there was no 
significant effect; as demonstrated by Western blotting (Figure 5A) and confirmed by 
densitometric analysis (Figure 5B). Thus, our hypothesis that the bacterial ligand Pam3CSK4 
attenuated upregulation of MKP-1 protein was not supported. 
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3.5 Corticosteroid insensitivity may be due to Pam3CSK4-induced oxidization of MKP-
1  
However, MKP-1 protein is subject to redox regulation (Hou et al., 2008; Kamata et al., 
2005) as the catalytic cysteine responsible for phosphatase action can be oxidized and thus 
reduce anti-inflammatory function (Bonham and Vacratsis, 2009). Notably, Pam3CSK4 has 
been shown to increase oxidative stress in a TLR2-mediated manner (Singh et al., 2015). To 
test this in A549 cells we measured the expression of heme oxygenase 1 as a surrogate 
measure of oxidative stress. HO-1 is an inducible enzyme that can be detected by Western 
blotting and a recognised marked of oxidative stress (Kamalvand et al., 2003). We examined 
the effect of Pam3CSK4, alone and in combination with TNF, on HO-1 protein upregulation, 
and as shown in Figure 6, Pam3CSK4 significantly increases HO-1 protein upregulation as 
detected by Western blotting (Figure 6A) and assessed densitometrically (Figure 
6B)(P<0.05). The increases in HO-1 upregulation were similar to those achieved with 100 
µM H2O2 (Figure 6), a positive control for oxidative stress  
We were now intrigued to examine whether MKP-1 expressed under these conditions may be 
oxidized. To do this, we utilized a technique referred to as PROP (purification of reversibly 
oxidized proteins) (Templeton et al., 2010; Victor et al., 2012). A549 cells were treated under 
conditions established above to induce corticosteroid insensitivity (dexamethasone (at 10 nM) 
+ TNF without/with Pam3CSK4) in order to ask the question - is the MKP-1 produced in 
cells that have been pretreated with Pam3CSK4 oxidized? In order to show that Pam3CSK4 
increases MKP-1 oxidation, experiments were performed in parallel, and then either prepared 
as whole cell lysates to measure native MKP-1, or subjected to the PROP technique to detect 
oxidized MKP-1. As shown in Figures 7A and 7B, and in confirmation with our earlier data 
(Figure 5), Pam3CSK4 had no significant effect on the dexamethasone + TNF-induced 
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upregulation of MKP-1 detected in whole cell lysates (see native MKP-1 (WCL)). In 
contrast, there was a significant (P<0.05) increase in oxidized MKP-1 detected by the PROP 
technique (Figure 7B). To examine whether this oxidized MKP-1 resulted in altered MKP-1 
activity and an impact on downstream effectors, we examined the phosphorylation of MAPK 
superfamily members (p38 MAPK, ERK and JNK) under identical conditions. These data are 
shown by Western blot in Figure 7C and densitometrically in Figure 7D, where we see a 
small but significant increase in p38 MAPK phosphorylation in the presence of Pam3CSK4 
(P<0.05). ERK phosphorylation was unaffected, while there was some variability in the JNK 
response. In cells pretreated with the widely-used positive control for oxidative stress – H2O2 
(Kamata et al., 2005; Templeton et al., 2010; Victor et al., 2012) before TNF, we can 
confirm that the PROP technique detects increases in oxidized MKP-1 (Figures 7E and 7F). 
Taken together these results suggest that MKP-1 oxidation induced by Pam3CSK4 may be a 
contributing factor in corticosteroid insensitivity. 
 
3.6 Alternative anti-inflammatory approaches to overcome corticosteroid insensitivity: 
known and novel PP2A activators 
By modeling bacterial exacerbation in vitro we have demonstrated that exposure to a 
bacterial ligand induces corticosteroid insensitivity. We revealed, in part, a contributing 
molecular mechanism (oxidation of MKP-1) and show that translocation of GR and p65 NF-
κB is unaffected. We now turn to exploring alternative anti-inflammatory approaches and 
hypothesize that PP2A activators, being non-steroidal, may prove to inhibit cytokine 
production when corticosteroid insensitivity exists. To address this we examine the impact of 
two compounds: FTY720 and theophylline. FTY720 is a well-established activator of PP2A 
(Perrotti and Neviani, 2013; Rahman et al., 2015); while theophylline has only been recently 
reported by us (Patel et al., 2015) to function as a novel activator of PP2A. The 
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concentrations of FTY720 and theophylline utilized in this study were in accordance with 
previous publications (Patel et al., 2015; Rahman et al., 2015). We show that FTY720 (2.5 
µM) in combination with dexamethasone (0.001-1 µM) achieves significant repression of IL-
6 with lower concentrations of corticosteroids (Figure 8A), and inhibits IL-6 secretion in cells 
where corticosteroid insensitivity has been established by exposure to the bacterial ligand 
Pam3CSK4 (Alkhouri et al., 2014; Manetsch et al., 2012c)(Figure 8B) (P<0.05).  At a 
concentration of 10 µM, theophylline is anti-inflammatory and can repress TNF-induced 
IL-6 secretion (Figure 9A); in confirmation of our earlier publication (Patel et al., 2015). It 
also appeared to have an additive repressive effect together with corticosteroids, although this 
difference was not significant. However, theophylline can still significantly repress IL-6 
secretion even when corticosteroid insensitivity exists (Figure 9B: P<0.05). Thus, PP2A 
activators are a non-steroidal anti-inflammatory alternative and/or corticosteroid-sparing 
approach in respiratory inflammation where corticosteroid insensitivity exists.  
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4. Discussion 
Corticosteroid insensitivity is a major factor limiting treatment of chronic respiratory disease 
today. The relative responsiveness to corticosteroids can be influenced by a range of 
endogenous and exogenous factors, including respiratory infections. In this study we modeled 
bacterial infection in vitro and showed for the first time that ligation of the TLR2 receptor 
with a synthetic bacterial lipoprotein induces corticosteroid insensitivity. We then explored 
the cellular mechanisms responsible and demonstrate that, unlike rhinoviral-induced 
corticosteroid insensitivity, Pam3CSK4 did not perturb GR nuclear translocation. Notably, 
while the overall amount of native MKP-1 upregulation protein produced under these 
conditions was unaffected by Pam3CSK4 pretreatment, a significant proportion of MKP-1 
was oxidized and consequently was rendered inactive. Finally, we explored alternative 
modalities to repress cytokine production and demonstrate the utility of PP2A activators as 
non-steroidal anti-inflammatory alternatives and/or corticosteroid-sparing approaches in 
respiratory inflammation where corticosteroid insensitivity exists. 
When a person with chronic lung disease (such as asthma and COPD) experiences an 
infection their lung function deteriorates and they require greater amounts of their anti-
inflammatory medicines to treat their respiratory symptoms. This is because viral or bacterial 
infection changes the molecular pathways by which respiratory medicines act; making them 
less sensitive. These changes are due to interaction of viral and bacterial products with 
pattern recognition receptors, particularly TLRs expressed on airway cells (reviewed in 
(Saturni et al., 2015)). We have focused on mimicking bacterial infection in vitro with 
Pam3CSK4 and have previously shown that TLR2 ligation robustly increased TNF-induced 
secretion of cytokines implicated as playing a role in exacerbation (Manetsch et al., 2012c). 
Moreover, TLR2 activation causes tachyphylaxis to bronchodilatory β2-agonists in vitro and 
ex vivo (Alkhouri et al., 2014). In the current study, we reveal an additional detrimental 
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consequence of bacterial infection beyond amplification of inflammation and β2-adrenergic 
desensitization; namely, we show that Pam3CSK4 induces corticosteroid insensitivity. This 
in vitro evidence is in support of a recent study examining clinical samples from people with 
COPD that linked increased TLR2 with this corticosteroid insensitive condition (Simpson et 
al., 2013). 
However, the molecular mechanisms responsible differ from those reported for corticosteroid 
insensitivity induced in A549 cells by rhinoviral infection (Papi et al., 2013).  Corticosteroids 
initiate their effects on gene expression by interacting with cytoplasmic GRs. Translocation 
of GR into the nucleus is a requisite step to allow GR to act as a ligand-dependent 
transcription factor. Once in the nucleus, ligand-activated GRs then repress inflammation by: 
(i) activation of glucocorticoid response elements and upregulation of anti-inflammatory 
genes, including MKP-1 and glucocorticoid-inducible leucine zipper 1; (ii) inhibitory 
interactions with proinflammatory DNA-binding transcription factors, such as NF-B; and 
(iii) effects on recruitment of transcriptional co-activators, co-repressors and the chromatin 
machinery (reviewed in (Ammit, 2013)). Papi et al. (Papi et al., 2013) showed that rhinoviral 
infection reduced GR nuclear translocation, thus levels of MKP-1 upregulation was lower. 
Additionally, they demonstrated induction of MAPK signaling pathways (JNK in particular) 
and NF-B activation. In contrast, we show that GR translocation was unaffected by 
Pam3CSK4 and that the upregulation of MKP-1 in whole cell lysates was unchanged. We 
also confirm that corticosteroids have no effect on TNFα-induced IκB-α degradation and p65 
NF-κB nuclear entry, excluding the possibility that corticosteroid insensitivity is due to 
inhibitory interactions with the pro-inflammatory DNA-binding transcription factors, 
particularly NF-κB. 
However, just examining the overall protein levels of MKP-1 may not reveal the entire story. 
It is increasingly recognized that the MAPK-deactivating ability of dual-specificity 
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phosphatases (with MKP-1, aka DUSP1, being a founding member of this family) can be 
regulated post-translationally by oxidation (Bonham and Vacratsis, 2009). The catalytic 
cysteine of MKP-1 can be modified by oxidation, thereby reducing its function as 
phosphatase. Redox regulation of MKP-1 has been demonstrated in vitro (Hou et al., 2008; 
Kamata et al., 2005) and highlighted as a potential mechanism responsible for corticosteroid 
insensitivity in our recent in vivo study exposing MKP-1 wild-type and knock-out mice to 
ozone (Pinart et al., 2014). Notably, Pam3CSK4 can increase oxidative stress in a TLR2-
mediated manner (Singh et al., 2015) and herein we show that Pam3CSK4 increases 
production of a surrogate marker for oxidative stress, HO-1. Therefore we utilized the PROP 
technique to show that a proportion of MKP-1 expressed under these conditions is oxidized. 
This results in altered MKP-1 activity with impact on downstream effectors; notably 
p38MAPK phosphorylation is increased under these conditions. Taken together, these results 
suggest that Pam3CSK4-mediated oxidation of MKP-1 may contribute to corticosteroid 
insensitivity. 
Finally, we explored alternative means of repressing cytokines when corticosteroid 
insensitivity exists. We focused on small molecules that are known and novel activators of 
the ubiquitous serine-threonine phosphatase – PP2A. PP2A dephosphorylates a number of 
kinases that drive inflammatory cell signaling, including MAPKs and NF-B (Junttila et al., 
2008; Miskolci et al., 2003; Rahman et al., 2015; Shanley et al., 2001). A number of small 
molecules can activate PP2A (Perrotti and Neviani, 2013). The best known of these is 
FTY720, and we recently showed that it activates TNF-induced PP2A enzymatic activity 
and represses cytokine production in A549 cells (Rahman et al., 2015). In the current study 
we examine its efficacy when used as an adjunct therapy with corticosteroids in vitro and 
show that FTY720 can act additively in a corticosteroid-sparing manner. Most importantly in 
the context of the bacterial exacerbation, FTY720 can significantly repress cytokine 
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production when corticosteroid insensitivity exists. Lastly, we explored the potential effects 
of theophylline. Theophylline has beneficial effects in asthma and COPD and acts via a 
number of different molecular pathways (reviewed in (Barnes, 2013)). We recently reported a 
new anti-inflammatory function for theophylline; it increases TNF-induced PP2A 
enzymatic activity in A549 cells, as well as primary cultures of airway smooth muscle (Patel 
et al., 2015). Thus, we examined its impact on corticosteroid insensitivity and although the 
impact was not as great as FTY720, theophylline was able overcome corticosteroid 
insensitivity. It is important to note however, that we believe that these repressive effects on 
cytokine function exerted by FTY720 and theophylline are anti-inflammatory effects acting 
via alternative, PP2A-dependent pathways, rather than restoration of corticosteroid 
sensitivity, although further investigation is warranted.  
Collectively, our study shows that, like rhinoviral infection modeled in vitro, bacterial ligands 
exert corticosteroid insensitivity. These models allow us to explore the molecular 
mechanisms responsible and highlight potential therapeutic strategies to combat 
inflammation in infectious exacerbation. We reveal that oxidation of anti-inflammatory 
MKP-1, rather than retardation of nuclear translation, occurs via TLR2-mediated pathways. 
Finally, we suggest that activating PP2A may prove to be efficacious, non-steroidal anti-
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Figure 1. TLR2 ligand Pam3CSK4 induces corticosteroid insensitivity in A549 cells. 
A549 cells were pretreated for 30 min with either vehicle or Pam3CSK4 (1 µg/ml), followed 
by vehicle or dexamethasone (0.0001-1 µM) for 30 min. After stimulation with TNFα (4 
ng/ml) for 24 h, IL-6 was measured by ELISA. Statistical analysis was performed using two-
way ANOVA then Bonferroni’s post-test (where * denotes a significant reduction of 
corticosteroid-mediated repression by Pam3CSK4 (P<0.05)). Data are mean+SEM values 
from n=9 independent experiments. 
 
Figure 2. Corticosteroid insensitivity induced by Pam3CSK4 is not due to altered 
translocation of GR into the nucleus. A549 cells were pretreated for 30 min with either 
vehicle or Pam3CSK4 (1 µg/ml), followed by vehicle or dexamethasone (0.0001-1 µM) for 
30 min. GR translocation was examined in the (A) absence or (B) or presence of stimulation 
with TNFα (4 ng/ml) for 1 h. Cytoplasmic and nuclear protein extracts were prepared and 
nuclear entry of GR determined by Western blotting, compared with α-tubulin and lamin A/C 
as loading controls for the cytosolic and nuclear fractions, respectively. Data are 
representative blots from n=3 independent experiments. 
 
Figure 3. Corticosteroids have no effect on TNFα-induced IκB-α degradation. A549 cells 
were pretreated with vehicle or dexamethasone (0.0001-1 µM) for 30 min. Cells were then 
stimulated without and with TNFα (4 ng/ml) for 1 h and the impact on IκB-α degradation 
examined by Western blotting (with α-tubulin as the loading control). (A) Results are 
representative Western blots and (B) densitometric analysis of IκB-α degradation (expressed 
as a percentage of IκB-α measured in vehicle-treated cells, normalized to α-tubulin). 
Statistical analysis was performed using one-way ANOVA then Fisher’s post-hoc multiple 
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comparison test (where * denotes significant degradation of IκB-α induced by TNFα 
(P<0.05); there was no significant effect of dexamethasone). Data are mean+SEM values 
from n=3 independent experiments. 
 
Figure 4. Corticosteroids have no effect on TNFα-induced p65 NF-κB nuclear 
translocation. A549 cells were pretreated with vehicle or dexamethasone (0.0001-1 µM) for 
30 min. Cells were then stimulated without and with TNFα (4 ng/ml) for 1 h, nuclear protein 
extracts prepared and entry of p65 NF-κB into the nucleus determined by Western blotting, 
compared with lamin A/C as a loading control. (A) Results are representative Western blots 
and (B) densitometric analysis of p65 NF-κB nuclear translocation (expressed as fold 
increase in p65 NF-κB in the nucleus of vehicle-treated cells, normalized to lamin A/C). 
Statistical analysis was performed using one-way ANOVA then Fisher’s post-hoc multiple 
comparison test (where * denotes significant p65 NF-κB nuclear translocation induced by 
TNFα (P<0.05); there was no significant effect of dexamethasone). Data are mean+SEM 
values from n=3 independent experiments. 
 
Figure 5. Pam3CSK4 does not affect corticosteroid-induced upregulation of anti-
inflammatory MKP-1. A549 cells were pretreated for 30 min with either vehicle or 
Pam3CSK4 (1 µg/ml), followed by vehicle or dexamethasone (0.0001-1 µM) for 30 min. 
Cells were treated without and with TNFα (4 ng/ml) for 1 h and the impact on MKP-1 
upregulation compared by Western blotting (with α-tubulin as the loading control). (A) 
Results are representative Western blots and (B) densitometric analysis of MKP-1 protein 
upregulation (normalized to α-tubulin and expressed as fold increase compared to vehicle-
treated cells). Statistical analysis was performed using Student's unpaired t test or one-way 
ANOVA then Fisher’s post-hoc multiple comparison test (where * denotes significant 
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increase in MKP-1 protein upregulation induced by TNFα, and § denotes significant 
potentiation of TNFα-induced MKP-1 by dexamethasone (P<0.05); there was no effect of 
Pam3CSK4). Data are mean+SEM values from n=3 independent experiments. 
 
Figure 6. Pam3CSK4 increases heme oxygenase 1 (HO-1) protein upregulation: a 
marker of oxidative stress. A549 cells were treated for 2 h with either vehicle, Pam3CSK4 
(1 µg/ml) or H2O2 (100 µM) as a positive control for oxidative stress. HO-1 upregulation was 
examined by Western blotting (with α-tubulin as the loading control). (A) Results are 
representative Western blots and (B) densitometric analysis of HO-1 protein upregulation 
(expressed as a fold increase compared to vehicle-treated cells, normalized to α-tubulin). 
Statistical analysis was performed using one-way ANOVA then Fisher’s post-hoc multiple 
comparison test (where * denotes significant upregulation of HO-1 induced by both 
Pam3CSK4 and H2O2 (P<0.05)). Data are mean+SEM values from n=3 independent 
experiments. 
 
Figure 7. Corticosteroid insensitivity may be due to Pam3CSK4-induced oxidization of 
MKP-1. (A-D) A549 cells were pretreated for 30 min with either vehicle or Pam3CSK4 (1 
µg/ml), followed by dexamethasone (0.01 µM) for 30 min then TNFα (4 ng/ml) for 1 h.  (A, 
B) In order to show that Pam3CSK4 increases MKP-1 oxidation, experiments were 
performed in parallel, and then either prepared as whole cell lysates (WCL) to measure native 
MKP-1, or subjected to the PROP technique to detect oxidized MKP-1 and Western blotting 
performed. (C, D) To demonstrate the impact of oxidized MKP-1 on downstream effectors, 
the phosphorylation of MAPK family members (p38 MAPK, ERK and JNK) in WCL were 
measured by Western blotting (normalized to total p38 MAPK, ERK and JNK, respectively). 
(E, F) As a positive control for oxidative stress, A549 cells were pretreated for 30 min 
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without and with 100 µM H2O2 before stimulation with TNFα (4 ng/ml) for 1 h and 
processed as above (A, B). (A, C, E) Results are representative Western blots and (B, D, F) 
densitometric analysis (results expressed as fold increase compared to cells treated without 
(A-D) Pam3CSK4 or (E-F) H2O2). Statistical analysis was performed using one-way 
ANOVA then Fisher’s post-hoc multiple comparison test or Student’s unpaired t test (where 
* denotes significant increase (P<0.05). Data are mean+SEM values from n=3-4 independent 
experiments. 
 
Figure 8. FTY720 is corticosteroid-sparing and overcomes corticosteroid insensitivity. 
A549 were pretreated for 6 h with vehicle or FTY720 (2.5 μM), before 30 min with (A) 
vehicle or (B) bacterial mimic Pam3CSK4 (1 μg/ml), then dexamethasone (0.0001-1 μM) for 
30 min. After 24 h with TNFα (4 ng/ml), IL-6 was measured by ELISA. Statistical analysis 
was performed using two-way ANOVA then Bonferroni’s post-test (where * denotes a 
significant effect of FTY720 (P<0.05)). Data are mean+SEM values from n=3 independent 
experiments. 
 
Figure 9. Theophylline is anti-inflammatory and can overcome corticosteroid 
insensitivity. A549 were pretreated for 30 min with (A) vehicle or (B) bacterial mimic 
Pam3CSK4 (1 μg/ml), then dexamethasone (0.0001-1 μM) for 30 min, without or with 
theophylline (10 µM). After 24 h with TNFα (4 ng/ml), IL-6 was measured by ELISA. 
Statistical analysis was performed using two-way ANOVA then Bonferroni’s post-test 
(where * denotes a significant effect of theophylline (P<0.05)). Data are mean+SEM values 
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Corticosteroids are effective anti-inflammatory therapies widely utilized in chronic 
respiratory diseases. But these medicines can lose their efficacy during respiratory infection 
resulting in disease exacerbation. Further in vitro research is required to understand how 
infection worsens lung function control in order to advance therapeutic options to treat 
infectious exacerbation in the future. In this study, we utilize a cellular model of bacterial 
exacerbation where we pretreat A549 lung epithelial cells with the synthetic bacterial 
lipoprotein Pam3CSK4 (a TLR2 ligand) to mimic bacterial infection and tumor necrosis 
factor α (TNFα) to simulate inflammation. Under these conditions, Pam3CSK4 induces 
corticosteroid insensitivity; demonstrated by substantially reduced ability of the 
corticosteroid dexamethasone to repress TNF-induced interleukin 6 secretion. We then 
explored the molecular mechanism responsible and found that corticosteroid insensitivity 
induced by bacterial mimics was not due to altered translocation of the glucocorticoid 
receptor into the nucleus, nor an impact on the NF-κB pathway. Moreover, Pam3CSK4 did 
not affect corticosteroid-induced upregulation of anti-inflammatory MAPK deactivating 
phosphatase - MKP-1. However, Pam3CSK4 can induce oxidative stress and we show that a 
proportion of the MKP-1 produced in response to corticosteroid in the context of TLR2 
ligation was rendered inactive by oxidation. Thus to combat inflammation in the context of 
bacterial exacerbation we sought to discover effective strategies that bypassed this road-
block. We show for the first time that known (FTY720) and novel (theophylline) activators of 
the phosphatase PP2A can serve as non-steroidal anti-inflammatory alternatives and/or 
corticosteroid-sparing approaches in respiratory inflammation where corticosteroid 
insensitivity exists.  
 
Keywords: corticosteroid insensitivity, TLR2, MKP-1, PP2A 
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1. Introduction 
Corticosteroids are front-line anti-inflammatory therapies that are widely used to treat people 
with chronic lung disease. In asthma, although corticosteroids have proven clinical efficacy, 
it is increasingly recognized that their anti-inflammatory effectiveness can vary widely 
depending on disease context (such as when people with asthma are experiencing respiratory 
infections). This is known as corticosteroid insensitivity. In severe asthma, the degree of 
insensitivity increases to become corticosteroid resistance; a steroid-refractory condition 
experienced by 10% of people with asthma. Thus, the impact of corticosteroid insensitivity is 
increasingly recognized as a major problem limiting the efficacy of anti-inflammatory 
therapy in chronic respiratory disease (reviewed in (Ammit, 2013; Chung, 2013)). Moreover, 
corticosteroids are much less effective in chronic obstructive pulmonary disease (COPD) than 
in asthma, and this is considered due to relative corticosteroid insensitivity that exists in 
COPD (Marwick and Chung, 2010). To combat inflammation, steroid dose can be increased, 
but this is not ideal. Thus, alternative anti-inflammatory strategies that could effectively treat 
inflammation when corticosteroid insensitivity exists are urgently required. 
Cellular models of corticosteroid insensitivity are invaluable in vitro tools in our quest to 
develop novel and efficacious pharmacotherapeutic strategies to treat respiratory disease in 
the future. They are an essential first step towards elucidating the mechanisms responsible for 
respiratory infections and the exacerbation of chronic lung diseases. This was highlighted in a 
recent review by Saturni et al. (Saturni et al., 2015), and demonstrated by Papi et al. (Papi et 
al., 2013), where A549 lung epithelial cells exposed in vitro to rhinoviral infection resulted in 
corticosteroid insensitivity. The molecular mechanisms responsible were explored and shown 
to be due to reduced nuclear translocation of the receptor for corticosteroids – the 
glucocorticoid-receptor (GR) (Papi et al., 2013). Ligand-activated GR translocation is a 
critical step in corticosteroid function; without this, GRs are unable to interact in a cis- or 
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trans-manner to exert transcriptional control. Notably, upregulation of a critical, 
corticosteroid-induced, anti-inflammatory protein – mitogen-activated protein kinase 
phosphatase 1 (MKP-1) - was attenuated by rhinoviral infection and contributed to 
corticosteroid insensitivity. While the impact of respiratory viruses on corticosteroid 
insensitivity have begun to be uncovered (reviewed in (Saturni et al., 2015)), the influence of 
bacterial infection warrants further investigation. 
Accordingly, we have established an in vitro cellular model of bacterial exacerbation utilizing 
the synthetic bacterial lipoprotein Pam3CSK4 (Alkhouri et al., 2014; Hirota et al., 2013; 
Manetsch et al., 2012c). The impact of this TLR2 ligand on corticosteroid insensitivity and 
the role played by GR translocation and MKP-1 upregulation was previously unknown. We 
address this herein and show that Pam3CSK4 induces corticosteroid insensitivity in A549 
lung epithelial cells. Interestingly, the mechanism is not via retardation of GR translocation 
into the nucleus, the mechanism responsible for rhinoviral-induced corticosteroid 
insensitivity (Papi et al., 2013). Instead we reveal that while the total amount of anti-
inflammatory MKP-1 produced in response to corticosteroid in the context of TLR2 ligation 
was unaffected, a proportion of MKP-1 was rendered inactive by oxidation of the catalytic 
cysteine. MKP-1 is one of the major ways in which corticosteroids achieve anti-inflammatory 
action (Che et al., 2014; Issa et al., 2007; King et al., 2009; Manetsch et al., 2012a; Quante et 
al., 2008; Rahman et al., 2014). Given that this anti-inflammatory pathway is less effective 
under in vitro conditions mimicking bacterial exacerbation, we were compelled to uncover 
alternative, non-steroidal anti-inflammatory strategies. We focused on activators of 
ubiquitous serine/threonine phosphatase protein phosphatase 2A (PP2A). PP2A 
dephosphorylates a number of proteins that control inflammatory cell signalling (Junttila et 
al., 2008; Miskolci et al., 2003; Shanley et al., 2001) and our recent research has revealed that 
known and novel PP2A activators can also have substantial anti-inflammatory effect in the 
 5 
context of respiratory inflammation (Patel et al., 2015; Rahman et al., 2016; Rahman et al., 
2015). In this study we are the first to examine the impact of PP2A activators in an in vitro 
model of bacterial exacerbation, and notably, we show that PP2A activators can repress 
inflammation when corticosteroid insensitivity exists. 
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2. Material and Methods 
2.1 Chemicals 
Pam3CSK4 was purchased from InVivoGen (San Diego, CA), tumor necrosis factor  
(TNFα) was from R&D Systems (Minneapolis, MN) and FTY720 was from Cayman 
Chemical Company (Ann Arbor, MI). Unless otherwise specified, all chemicals used in this 
study were purchased from Sigma-Aldrich (St. Louis, MO).  
 
2.2 Cell culture 
The human alveolar epithelial cell line (A549) was cultured in Ham's F-12K (Kaighn's) 
medium (Invitrogen, Carlsbad, CA) supplemented with penicillin (100 U/ml), streptomycin 
(100 μg/ml), and fetal calf serum (10%). All experiments were performed after an overnight 
serum-starvation period (14-16 h) in Ham's F-12K supplemented with sterile BSA (0.1%), 
and cells were stimulated with 4 ng/ml TNFα in accordance with previous publications 
(Cornell et al., 2009; Rahman et al., 2015). A minimum of three experimental replicates 
performed on separate days were used for each experiment. 
 
2.3 ELISA 
IL-6 ELISA was performed according to the manufacturer’s instructions (BD Biosciences 
Pharmingen, San Diego, CA).    
 
2.4 Western blotting 
To examine GR and p65 NF-κB translocation, cytoplasmic and nuclear protein extraction 
was performed using NE-PER nuclear and cytosolic extraction kit according to the 
manufacturer's instructions (Thermo Fisher Scientific, Rockford, IL). Western blotting was 
performed using rabbit polyclonal IgG antibodies raised against GR (E-20: Santa Cruz 
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Biotechnology, Santa Cruz, CA) or an XP® rabbit monoclonal antibody against p65 NF-κB 
(D14E12: Cell Signaling Technologies, Danvers, MA). Mouse monoclonal antibodies to α-
tubulin (IgG1, DM1A: Santa Cruz Biotechnology) and rabbit polyclonal antibodies to lamin 
A/C (Cell Signaling Technology) were used as loading controls for the cytosolic and nuclear 
fractions, respectively. To measure MKP-1upregulation in whole cell lysates, MKP-1 was 
quantified by Western blotting using a rabbit polyclonal antibody against MKP-1 (C-19: 
Santa Cruz Biotechnology). IκB-α degradation and heme oxygenase 1 (HO-1) upregulation 
were also detected using rabbit polyclonal antibodies from Santa Cruz (C19) or Cell 
Signaling Technologies (P249), respectively. For all experiments in whole cell lysates, α-














) and total JNK were from Cell Signaling Technology. Primary 
antibodies were detected with goat anti-rabbit and anti-mouse HRP-conjugated secondary 
antibodies (Cell Signaling Technology) and visualized by enhanced chemiluminescence 
(PerkinElmer, Wellesley, MA).  
 
2.5 MKP-1 oxidation 
The method used to measure oxidized MKP-1 was an adaptation of the PROP (purification of 
reversibly oxidized proteins) technique developed by Templeton et al. (Templeton et al., 
2010; Victor et al., 2012). A549 cells were subjected to oxidative stress conditions (see 
experimental text) before commencing the PROP procedure. Briefly, the non-oxidized thiols 
were blocked using N-ethylmaleimide, then the oxidized thiols were reduced with 
dithiothrietol and eluted with thiol affinity chromatography (thiopropyl sepharose 6B: GE 
Healthcare, Little Chlafont, UK). Oxidized MKP-1 was then measured using Western blot 
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and the degree of oxidation compared to native MKP-1 measured in whole cell lysates run in 
parallel. 
 
2.6 Statistical analysis 
Statistical analysis was performed using either the Student's unpaired t test, one-way 
ANOVA with Fisher’s post-hoc multiple comparison test or two-way ANOVA followed by 
Bonferroni’s post-test. P values <0.05 were sufficient to reject the null hypothesis for all 
analyses. Data are mean+SEM of n≥3 independent replicates. 
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3. Results 
3.1 TLR2 ligand Pam3CSK4 induces corticosteroid insensitivity in A549 cells 
Herein we adapt a clinically-relevant model of corticosteroid insensitivity (Papi et al., 2013) 
to mimic bacterial exacerbation in vitro and demonstrate that exposure to a synthetic bacterial 
lipoprotein (TLR2/TLR1 ligand; Pam3CSK4) induces relative corticosteroid insensitivity. 
We chose to use 1 µg/ml Pam3CSK4 based on our earlier studies with this bacterial mimic 
(Hirota et al., 2013; Manetsch et al., 2012c). When A549 cells were pretreated with 
Pam3CSK4, the dose-dependent repression of TNF-induced IL-6 secretion achieved with 
dexamethasone was significantly altered (Figure 1: P<0.05). This is particularly notable at 
0.01-1 µM dexamethasone, where the inhibitory impact of dexamethasone on cytokine 
secretion from A549 cells is significantly attenuated by Pam3CSK4 (Figure 1: P<0.05). 
 
3.2 Corticosteroid insensitivity induced by Pam3CSK4 is not due to altered 
translocation of GR into the nucleus 
We then wished to explore the molecular mechanism responsible for corticosteroid 
insensitivity exerted by the TLR2 ligand. Corticosteroids mediate their actions via interaction 
with the cytosolic GR that then undergoes translocation into the nucleus. As this is an 
essential step necessary for corticosteroid action, we examined whether the molecular basis 
of corticosteroid insensitivity established by Pam3CSK4 is due to a retardation of GR 
translocation. We address this in Figure 2, where the effect of Pam3CSK4 pretreatment on 
GR translocation induced by dexamethasone (0.0001-1 µM) was assessed under two 
experimental conditions: i.e. in the absence (Figure 2A) or presence of stimulation with 
TNFα (Figure 2B). Cytoplasmic and nuclear protein extracts were prepared and nuclear entry 
of GR determined by Western blotting, compared with α-tubulin and lamin A/C as loading 
controls for the cytosolic and nuclear fractions, respectively. As shown in Figure 2A, GR 
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resides in the cytosol and is undetectable in the nucleus under unstimulated conditions. After 
treatment with dexamethasone however, GR undergoes translocation in a concentration-
dependent manner. Notably, dexamethasone-induced GR translocation is unaffected by 
Pam3CSK4 (Figure 2A). These results were independent of stimulation with TNF; as 
confirmatory experiments (performed in Figure 2B) show a similar pattern of GR 
translocation in cells that have been treated with TNF. Taken together these experiments 
demonstrate that corticosteroid insensitivity induced by Pam3CSK4 is not due to altered 
translocation of GR into the nucleus. 
 
3.3 Corticosteroids have no effect on TNFα-induced IκB-α degradation and p65 NF-κB 
nuclear entry 
Corticosteroids also have the potential to form inhibitory interactions with the pro-
inflammatory DNA-binding transcription factors, such as NF-κB (reviewed in (Ammit, 
2013)). To exclude the possible inhibition of NF-κB activity as a mechanism for 
corticosteroid insensitivity we took two experimental approaches. Firstly, we showed that 
corticosteroids had no effect on TNFα-induced IκB-α degradation (Figure 3). IκB-α is a 
constitutively expressed protein that forms an inhibitory complex with NF-κB. TNFα can 
induce the degradation of IκB-α, freeing NF-κB from its inhibitory control and allowing it to 
exert transcriptional impact. This is shown in Figure 3, where the basal level of inhibitory 
IκB-α is significantly degraded by TNFα. Notably, corticosteroids do not affect TNFα-
induced IκB-α degradation in A549 cells. We examined this after pretreating cells with a 
range of dexamethasone concentrations (0.0001-1 µM) and, as shown in Figure 3, there was 
no significant effect on the extent of IκB-α degradation achieved with TNFα in the presence 
of dexamethasone (P<0.05). Secondly, we examined whether dexamethasone repressed the 
translocation of the p65 NF-κB subunit into the nucleus. Cells were pretreated with a range of 
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dexamethasone concentrations (0.0001-1 µM) and the effect on TNFα-induced nuclear 
translocation assessed. As shown in Figure 4, corticosteroids have no effect on the nuclear 
entry of p65 NF-κB induced by TNFα. Taken together, the results presented in Figures 3 and 
4 confirm that corticosteroids do not act to repress the TNFα-induced NF-κB pathway.  
 
3.4 Pam3CSK4 does not affect corticosteroid-induced upregulation of anti-
inflammatory MKP-1 
Thus far we have shown that Pam3CSK4 reduces the anti-inflammatory efficacy of 
corticosteroids on TNF-induced cytokine production without affecting GR nor p65 NF-κB 
translocation. We (Che et al., 2014; Manetsch et al., 2012b; Quante et al., 2008; Rahman et 
al., 2014) and others (Issa et al., 2007; King et al., 2009) have shown that a major mechanism 
responsible for the anti-inflammatory action of corticosteroids is via the upregulation of 
MAPK-deactivating phosphatase – MKP-1; thus, we investigated whether impaired MKP-1 
upregulation was responsible for corticosteroid insensitivity induced by bacterial ligand 
Pam3CSK4. This is explored in Figure 5, where MKP-1 upregulation in whole cell lysates of 
A549 cells was compared by Western blotting (Figure 5A) and analyzed by densitometry 
(Figure 5B). We demonstrate that TNF induces significant upregulation of MKP-1 protein 
(3.2±0.5-fold compared to vehicle-treated cells (designated as 1) (P<0.05)); in alignment with 
previous studies in A549 cells (King et al., 2009). MKP-1 is corticosteroid-inducible (King et 
al., 2009) and accordingly, TNF-induced MKP-1 in A549 cells pretreated with 
dexamethasone is significantly enhanced at 0.01-1 µM (Figure 5B: P<0.05). However, when 
we examine the influence of Pam3CSK4 pretreatment on MKP-1 upregulation there was no 
significant effect; as demonstrated by Western blotting (Figure 5A) and confirmed by 
densitometric analysis (Figure 5B). Thus, our hypothesis that the bacterial ligand Pam3CSK4 
attenuated upregulation of MKP-1 protein was not supported. 
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3.5 Corticosteroid insensitivity may be due to Pam3CSK4-induced oxidization of MKP-
1  
However, MKP-1 protein is subject to redox regulation (Hou et al., 2008; Kamata et al., 
2005) as the catalytic cysteine responsible for phosphatase action can be oxidized and thus 
reduce anti-inflammatory function (Bonham and Vacratsis, 2009). Notably, Pam3CSK4 has 
been shown to increase oxidative stress in a TLR2-mediated manner (Singh et al., 2015). To 
test this in A549 cells we measured the expression of heme oxygenase 1 as a surrogate 
measure of oxidative stress. HO-1 is an inducible enzyme that can be detected by Western 
blotting and a recognised marked of oxidative stress (Kamalvand et al., 2003). We examined 
the effect of Pam3CSK4, alone and in combination with TNF, on HO-1 protein upregulation, 
and as shown in Figure 6, Pam3CSK4 significantly increases HO-1 protein upregulation as 
detected by Western blotting (Figure 6A) and assessed densitometrically (Figure 
6B)(P<0.05). The increases in HO-1 upregulation were similar to those achieved with 100 
µM H2O2 (Figure 6), a positive control for oxidative stress  
We were now intrigued to examine whether MKP-1 expressed under these conditions may be 
oxidized. To do this, we utilized a technique referred to as PROP (purification of reversibly 
oxidized proteins) (Templeton et al., 2010; Victor et al., 2012). A549 cells were treated under 
conditions established above to induce corticosteroid insensitivity (dexamethasone (at 10 nM) 
+ TNF without/with Pam3CSK4) in order to ask the question - is the MKP-1 produced in 
cells that have been pretreated with Pam3CSK4 oxidized? In order to show that Pam3CSK4 
increases MKP-1 oxidation, experiments were performed in parallel, and then either prepared 
as whole cell lysates to measure native MKP-1, or subjected to the PROP technique to detect 
oxidized MKP-1. As shown in Figures 7A and 7B, and in confirmation with our earlier data 
(Figure 5), Pam3CSK4 had no significant effect on the dexamethasone + TNF-induced 
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upregulation of MKP-1 detected in whole cell lysates (see native MKP-1 (WCL)). In 
contrast, there was a significant (P<0.05) increase in oxidized MKP-1 detected by the PROP 
technique (Figure 7B). To examine whether this oxidized MKP-1 resulted in altered MKP-1 
activity and an impact on downstream effectors, we examined the phosphorylation of MAPK 
superfamily members (p38 MAPK, ERK and JNK) under identical conditions. These data are 
shown by Western blot in Figure 7C and densitometrically in Figure 7D, where we see a 
small but significant increase in p38 MAPK phosphorylation in the presence of Pam3CSK4 
(P<0.05). ERK phosphorylation was unaffected, while there was some variability in the JNK 
response. In cells pretreated with the widely-used positive control for oxidative stress – H2O2 
(Kamata et al., 2005; Templeton et al., 2010; Victor et al., 2012) before TNF, we can 
confirm that the PROP technique detects increases in oxidized MKP-1 (Figures 7E and 7F). 
Taken together these results suggest that MKP-1 oxidation induced by Pam3CSK4 may be a 
contributing factor in corticosteroid insensitivity. 
 
3.6 Alternative anti-inflammatory approaches to overcome corticosteroid insensitivity: 
known and novel PP2A activators 
By modeling bacterial exacerbation in vitro we have demonstrated that exposure to a 
bacterial ligand induces corticosteroid insensitivity. We revealed, in part, a contributing 
molecular mechanism (oxidation of MKP-1) and show that translocation of GR and p65 NF-
κB is unaffected. We now turn to exploring alternative anti-inflammatory approaches and 
hypothesize that PP2A activators, being non-steroidal, may prove to inhibit cytokine 
production when corticosteroid insensitivity exists. To address this we examine the impact of 
two compounds: FTY720 and theophylline. FTY720 is a well-established activator of PP2A 
(Perrotti and Neviani, 2013; Rahman et al., 2015); while theophylline has only been recently 
reported by us (Patel et al., 2015) to function as a novel activator of PP2A. The 
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concentrations of FTY720 and theophylline utilized in this study were in accordance with 
previous publications (Patel et al., 2015; Rahman et al., 2015). We show that FTY720 (2.5 
µM) in combination with dexamethasone (0.001-1 µM) achieves significant repression of IL-
6 with lower concentrations of corticosteroids (Figure 8A), and inhibits IL-6 secretion in cells 
where corticosteroid insensitivity has been established by exposure to the bacterial ligand 
Pam3CSK4 (Alkhouri et al., 2014; Manetsch et al., 2012c)(Figure 8B) (P<0.05).  At a 
concentration of 10 µM, theophylline is anti-inflammatory and can repress TNF-induced 
IL-6 secretion (Figure 9A); in confirmation of our earlier publication (Patel et al., 2015). It 
also appeared to have an additive repressive effect together with corticosteroids, although this 
difference was not significant. However, theophylline can still significantly repress IL-6 
secretion even when corticosteroid insensitivity exists (Figure 9B: P<0.05). Thus, PP2A 
activators are a non-steroidal anti-inflammatory alternative and/or corticosteroid-sparing 
approach in respiratory inflammation where corticosteroid insensitivity exists.  
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4. Discussion 
Corticosteroid insensitivity is a major factor limiting treatment of chronic respiratory disease 
today. The relative responsiveness to corticosteroids can be influenced by a range of 
endogenous and exogenous factors, including respiratory infections. In this study we modeled 
bacterial infection in vitro and showed for the first time that ligation of the TLR2 receptor 
with a synthetic bacterial lipoprotein induces corticosteroid insensitivity. We then explored 
the cellular mechanisms responsible and demonstrate that, unlike rhinoviral-induced 
corticosteroid insensitivity, Pam3CSK4 did not perturb GR nuclear translocation. Notably, 
while the overall amount of native MKP-1 upregulation protein produced under these 
conditions was unaffected by Pam3CSK4 pretreatment, a significant proportion of MKP-1 
was oxidized and consequently was rendered inactive. Finally, we explored alternative 
modalities to repress cytokine production and demonstrate the utility of PP2A activators as 
non-steroidal anti-inflammatory alternatives and/or corticosteroid-sparing approaches in 
respiratory inflammation where corticosteroid insensitivity exists. 
When a person with chronic lung disease (such as asthma and COPD) experiences an 
infection their lung function deteriorates and they require greater amounts of their anti-
inflammatory medicines to treat their respiratory symptoms. This is because viral or bacterial 
infection changes the molecular pathways by which respiratory medicines act; making them 
less sensitive. These changes are due to interaction of viral and bacterial products with 
pattern recognition receptors, particularly TLRs expressed on airway cells (reviewed in 
(Saturni et al., 2015)). We have focused on mimicking bacterial infection in vitro with 
Pam3CSK4 and have previously shown that TLR2 ligation robustly increased TNF-induced 
secretion of cytokines implicated as playing a role in exacerbation (Manetsch et al., 2012c). 
Moreover, TLR2 activation causes tachyphylaxis to bronchodilatory β2-agonists in vitro and 
ex vivo (Alkhouri et al., 2014). In the current study, we reveal an additional detrimental 
 16 
consequence of bacterial infection beyond amplification of inflammation and β2-adrenergic 
desensitization; namely, we show that Pam3CSK4 induces corticosteroid insensitivity. This 
in vitro evidence is in support of a recent study examining clinical samples from people with 
COPD that linked increased TLR2 with this corticosteroid insensitive condition (Simpson et 
al., 2013). 
However, the molecular mechanisms responsible differ from those reported for corticosteroid 
insensitivity induced in A549 cells by rhinoviral infection (Papi et al., 2013).  Corticosteroids 
initiate their effects on gene expression by interacting with cytoplasmic GRs. Translocation 
of GR into the nucleus is a requisite step to allow GR to act as a ligand-dependent 
transcription factor. Once in the nucleus, ligand-activated GRs then repress inflammation by: 
(i) activation of glucocorticoid response elements and upregulation of anti-inflammatory 
genes, including MKP-1 and glucocorticoid-inducible leucine zipper 1; (ii) inhibitory 
interactions with proinflammatory DNA-binding transcription factors, such as NF-B; and 
(iii) effects on recruitment of transcriptional co-activators, co-repressors and the chromatin 
machinery (reviewed in (Ammit, 2013)). Papi et al. (Papi et al., 2013) showed that rhinoviral 
infection reduced GR nuclear translocation, thus levels of MKP-1 upregulation was lower. 
Additionally, they demonstrated induction of MAPK signaling pathways (JNK in particular) 
and NF-B activation. In contrast, we show that GR translocation was unaffected by 
Pam3CSK4 and that the upregulation of MKP-1 in whole cell lysates was unchanged. We 
also confirm that corticosteroids have no effect on TNFα-induced IκB-α degradation and p65 
NF-κB nuclear entry, excluding the possibility that corticosteroid insensitivity is due to 
inhibitory interactions with the pro-inflammatory DNA-binding transcription factors, 
particularly NF-κB. 
However, just examining the overall protein levels of MKP-1 may not reveal the entire story. 
It is increasingly recognized that the MAPK-deactivating ability of dual-specificity 
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phosphatases (with MKP-1, aka DUSP1, being a founding member of this family) can be 
regulated post-translationally by oxidation (Bonham and Vacratsis, 2009). The catalytic 
cysteine of MKP-1 can be modified by oxidation, thereby reducing its function as 
phosphatase. Redox regulation of MKP-1 has been demonstrated in vitro (Hou et al., 2008; 
Kamata et al., 2005) and highlighted as a potential mechanism responsible for corticosteroid 
insensitivity in our recent in vivo study exposing MKP-1 wild-type and knock-out mice to 
ozone (Pinart et al., 2014). Notably, Pam3CSK4 can increase oxidative stress in a TLR2-
mediated manner (Singh et al., 2015) and herein we show that Pam3CSK4 increases 
production of a surrogate marker for oxidative stress, HO-1. Therefore we utilized the PROP 
technique to show that a proportion of MKP-1 expressed under these conditions is oxidized. 
This results in altered MKP-1 activity with impact on downstream effectors; notably 
p38MAPK phosphorylation is increased under these conditions. Taken together, these results 
suggest that Pam3CSK4-mediated oxidation of MKP-1 may contribute to corticosteroid 
insensitivity. 
Finally, we explored alternative means of repressing cytokines when corticosteroid 
insensitivity exists. We focused on small molecules that are known and novel activators of 
the ubiquitous serine-threonine phosphatase – PP2A. PP2A dephosphorylates a number of 
kinases that drive inflammatory cell signaling, including MAPKs and NF-B (Junttila et al., 
2008; Miskolci et al., 2003; Rahman et al., 2015; Shanley et al., 2001). A number of small 
molecules can activate PP2A (Perrotti and Neviani, 2013). The best known of these is 
FTY720, and we recently showed that it activates TNF-induced PP2A enzymatic activity 
and represses cytokine production in A549 cells (Rahman et al., 2015). In the current study 
we examine its efficacy when used as an adjunct therapy with corticosteroids in vitro and 
show that FTY720 can act additively in a corticosteroid-sparing manner. Most importantly in 
the context of the bacterial exacerbation, FTY720 can significantly repress cytokine 
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production when corticosteroid insensitivity exists. Lastly, we explored the potential effects 
of theophylline. Theophylline has beneficial effects in asthma and COPD and acts via a 
number of different molecular pathways (reviewed in (Barnes, 2013)). We recently reported a 
new anti-inflammatory function for theophylline; it increases TNF-induced PP2A 
enzymatic activity in A549 cells, as well as primary cultures of airway smooth muscle (Patel 
et al., 2015). Thus, we examined its impact on corticosteroid insensitivity and although the 
impact was not as great as FTY720, theophylline was able overcome corticosteroid 
insensitivity. It is important to note however, that we believe that these repressive effects on 
cytokine function exerted by FTY720 and theophylline are anti-inflammatory effects acting 
via alternative, PP2A-dependent pathways, rather than restoration of corticosteroid 
sensitivity, although further investigation is warranted.  
Collectively, our study shows that, like rhinoviral infection modeled in vitro, bacterial ligands 
exert corticosteroid insensitivity. These models allow us to explore the molecular 
mechanisms responsible and highlight potential therapeutic strategies to combat 
inflammation in infectious exacerbation. We reveal that oxidation of anti-inflammatory 
MKP-1, rather than retardation of nuclear translation, occurs via TLR2-mediated pathways. 
Finally, we suggest that activating PP2A may prove to be efficacious, non-steroidal anti-
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Figure 1. TLR2 ligand Pam3CSK4 induces corticosteroid insensitivity in A549 cells. 
A549 cells were pretreated for 30 min with either vehicle or Pam3CSK4 (1 µg/ml), followed 
by vehicle or dexamethasone (0.0001-1 µM) for 30 min. After stimulation with TNFα (4 
ng/ml) for 24 h, IL-6 was measured by ELISA. Statistical analysis was performed using two-
way ANOVA then Bonferroni’s post-test (where * denotes a significant reduction of 
corticosteroid-mediated repression by Pam3CSK4 (P<0.05)). Data are mean+SEM values 
from n=9 independent experiments. 
 
Figure 2. Corticosteroid insensitivity induced by Pam3CSK4 is not due to altered 
translocation of GR into the nucleus. A549 cells were pretreated for 30 min with either 
vehicle or Pam3CSK4 (1 µg/ml), followed by vehicle or dexamethasone (0.0001-1 µM) for 
30 min. GR translocation was examined in the (A) absence or (B) or presence of stimulation 
with TNFα (4 ng/ml) for 1 h. Cytoplasmic and nuclear protein extracts were prepared and 
nuclear entry of GR determined by Western blotting, compared with α-tubulin and lamin A/C 
as loading controls for the cytosolic and nuclear fractions, respectively. Data are 
representative blots from n=3 independent experiments. 
 
Figure 3. Corticosteroids have no effect on TNFα-induced IκB-α degradation. A549 cells 
were pretreated with vehicle or dexamethasone (0.0001-1 µM) for 30 min. Cells were then 
stimulated without and with TNFα (4 ng/ml) for 1 h and the impact on IκB-α degradation 
examined by Western blotting (with α-tubulin as the loading control). (A) Results are 
representative Western blots and (B) densitometric analysis of IκB-α degradation (expressed 
as a percentage of IκB-α measured in vehicle-treated cells, normalized to α-tubulin). 
Statistical analysis was performed using one-way ANOVA then Fisher’s post-hoc multiple 
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comparison test (where * denotes significant degradation of IκB-α induced by TNFα 
(P<0.05); there was no significant effect of dexamethasone). Data are mean+SEM values 
from n=3 independent experiments. 
 
Figure 4. Corticosteroids have no effect on TNFα-induced p65 NF-κB nuclear 
translocation. A549 cells were pretreated with vehicle or dexamethasone (0.0001-1 µM) for 
30 min. Cells were then stimulated without and with TNFα (4 ng/ml) for 1 h, nuclear protein 
extracts prepared and entry of p65 NF-κB into the nucleus determined by Western blotting, 
compared with lamin A/C as a loading control. (A) Results are representative Western blots 
and (B) densitometric analysis of p65 NF-κB nuclear translocation (expressed as fold 
increase in p65 NF-κB in the nucleus of vehicle-treated cells, normalized to lamin A/C). 
Statistical analysis was performed using one-way ANOVA then Fisher’s post-hoc multiple 
comparison test (where * denotes significant p65 NF-κB nuclear translocation induced by 
TNFα (P<0.05); there was no significant effect of dexamethasone). Data are mean+SEM 
values from n=3 independent experiments. 
 
Figure 5. Pam3CSK4 does not affect corticosteroid-induced upregulation of anti-
inflammatory MKP-1. A549 cells were pretreated for 30 min with either vehicle or 
Pam3CSK4 (1 µg/ml), followed by vehicle or dexamethasone (0.0001-1 µM) for 30 min. 
Cells were treated without and with TNFα (4 ng/ml) for 1 h and the impact on MKP-1 
upregulation compared by Western blotting (with α-tubulin as the loading control). (A) 
Results are representative Western blots and (B) densitometric analysis of MKP-1 protein 
upregulation (normalized to α-tubulin and expressed as fold increase compared to vehicle-
treated cells). Statistical analysis was performed using Student's unpaired t test or one-way 
ANOVA then Fisher’s post-hoc multiple comparison test (where * denotes significant 
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increase in MKP-1 protein upregulation induced by TNFα, and § denotes significant 
potentiation of TNFα-induced MKP-1 by dexamethasone (P<0.05); there was no effect of 
Pam3CSK4). Data are mean+SEM values from n=3 independent experiments. 
 
Figure 6. Pam3CSK4 increases heme oxygenase 1 (HO-1) protein upregulation: a 
marker of oxidative stress. A549 cells were treated for 2 h with either vehicle, Pam3CSK4 
(1 µg/ml) or H2O2 (100 µM) as a positive control for oxidative stress. HO-1 upregulation was 
examined by Western blotting (with α-tubulin as the loading control). (A) Results are 
representative Western blots and (B) densitometric analysis of HO-1 protein upregulation 
(expressed as a fold increase compared to vehicle-treated cells, normalized to α-tubulin). 
Statistical analysis was performed using one-way ANOVA then Fisher’s post-hoc multiple 
comparison test (where * denotes significant upregulation of HO-1 induced by both 
Pam3CSK4 and H2O2 (P<0.05)). Data are mean+SEM values from n=3 independent 
experiments. 
 
Figure 7. Corticosteroid insensitivity may be due to Pam3CSK4-induced oxidization of 
MKP-1. (A-D) A549 cells were pretreated for 30 min with either vehicle or Pam3CSK4 (1 
µg/ml), followed by dexamethasone (0.01 µM) for 30 min then TNFα (4 ng/ml) for 1 h.  (A, 
B) In order to show that Pam3CSK4 increases MKP-1 oxidation, experiments were 
performed in parallel, and then either prepared as whole cell lysates (WCL) to measure native 
MKP-1, or subjected to the PROP technique to detect oxidized MKP-1 and Western blotting 
performed. (C, D) To demonstrate the impact of oxidized MKP-1 on downstream effectors, 
the phosphorylation of MAPK family members (p38 MAPK, ERK and JNK) in WCL were 
measured by Western blotting (normalized to total p38 MAPK, ERK and JNK, respectively). 
(E, F) As a positive control for oxidative stress, A549 cells were pretreated for 30 min 
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without and with 100 µM H2O2 before stimulation with TNFα (4 ng/ml) for 1 h and 
processed as above (A, B). (A, C, E) Results are representative Western blots and (B, D, F) 
densitometric analysis (results expressed as fold increase compared to cells treated without 
(A-D) Pam3CSK4 or (E-F) H2O2). Statistical analysis was performed using one-way 
ANOVA then Fisher’s post-hoc multiple comparison test or Student’s unpaired t test (where 
* denotes significant increase (P<0.05). Data are mean+SEM values from n=3-4 independent 
experiments. 
 
Figure 8. FTY720 is corticosteroid-sparing and overcomes corticosteroid insensitivity. 
A549 were pretreated for 6 h with vehicle or FTY720 (2.5 μM), before 30 min with (A) 
vehicle or (B) bacterial mimic Pam3CSK4 (1 μg/ml), then dexamethasone (0.0001-1 μM) for 
30 min. After 24 h with TNFα (4 ng/ml), IL-6 was measured by ELISA. Statistical analysis 
was performed using two-way ANOVA then Bonferroni’s post-test (where * denotes a 
significant effect of FTY720 (P<0.05)). Data are mean+SEM values from n=3 independent 
experiments. 
 
Figure 9. Theophylline is anti-inflammatory and can overcome corticosteroid 
insensitivity. A549 were pretreated for 30 min with (A) vehicle or (B) bacterial mimic 
Pam3CSK4 (1 μg/ml), then dexamethasone (0.0001-1 μM) for 30 min, without or with 
theophylline (10 µM). After 24 h with TNFα (4 ng/ml), IL-6 was measured by ELISA. 
Statistical analysis was performed using two-way ANOVA then Bonferroni’s post-test 
(where * denotes a significant effect of theophylline (P<0.05)). Data are mean+SEM values 
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